Articles tagged with Leukemia
The E1912 follow-up analysis shows that ibrutinib-based therapy lived longer and with sustained benefit in previously untreated CLL patients. The majority of patients were well-tolerated, with only 14% stopping due to side effects.
Researchers at the University of Zurich have identified a new target for treating incurable leukemia in children by analyzing the molecular causes of the disease. They found that an abnormal protein activates genes at the wrong time, triggering the formation of malignant white blood cells and causing leukemia.
A new study found exposure to CT scans is associated with higher risks of developing thyroid cancer and leukemia. The risk is stronger in patients who have received multiple scans, particularly younger adults and females.
A clinical trial at St. Jude Children's Research Hospital found that adding chemotherapy doses in the cerebrospinal fluid improved CNS control without increasing toxicity for high-risk patients. The study reduced CNS relapse rates from 5.7% to 1.8%, making it the lowest among reported studies.
A months-old infant with rare childhood leukemia was treated with sorafenib, a targeted therapy approved for adults with inoperable liver cancer. The patient's unique genetic mutation led to a significant response to the treatment, highlighting the importance of identifying genetic mutations in cancer treatment.
Researchers have identified a potential combination targeted therapy for a deadly type of leukemia found in some infants, which was linked to high levels of the BCL6 protein and poor outcomes. The therapy involves 'turning off' the BCL6 protein using ABT-199, promising a lifesaving treatment option for babies and young children.
Researchers sequenced biopsies from pediatric patients with acute lymphoblastic leukemia and found that they harbored T cells specific to many neoepitopes. The patients' T cells responded to a significant proportion of these neoepitopes, forming hierarchies in their responses.
A study by Maxime Caru found that childhood ALL survivors have significantly worse cardiorespiratory fitness than healthy Canadians, with a 22% reduction. The research also identified specific trainability genes linked to the decline in cardiorespiratory fitness among female survivors.
Researchers have discovered a new treatment approach for T-cell acute lymphoblastic leukemia (T-ALL) that targets the Notch signaling pathway with greater safety and efficacy than previous treatments. The findings, published in Science Translational Medicine, show promise for translating this therapy to patients.
Researchers found that the combination of ibrutinib and venetoclax was highly effective in achieving complete remission with undetectable minimal residual disease in high-risk CLL patients. The study also showed that this combination therapy had no new toxic effects compared to individual agents.
Scientists at Johns Hopkins University have unraveled how the DNA machinery fits together, revealing a paradigm shift in understanding genetic illness. The discovery of how nucleosomes change shape to bind with an enzyme could unveil new treatment opportunities for childhood leukemia.
Researchers have shed light on how leukemia cells become resistant to drugs and describe a potential solution using two drugs in combination. The study identifies the genes responsible for resistance, revealing that cancer cells overcome the lack of asparagine by breaking down proteins.
Scientists identify CXCL12-expressing mesenchymal stromal cell niches as a strategy to target and eliminate treatment-resistant leukemic stem cells in chronic myelogenous leukemia. The study reveals that these niche interactions control quiescence of leukemic stem cells.
Researchers at Tel Aviv University developed a novel biosensor that can isolate and target leukemic stem cells, the most malignant of all leukemic cells. The sensor uses genetic encoding to identify and characterize these cells, which have high regenerative potential and escape targeted therapies.
Scientists at CeMM Research Center have developed a method to identify promising drug combinations for chronic lymphocytic leukemia. By combining epigenetic analysis and high-throughput imaging, researchers can predict which drugs are likely to work together effectively, reducing trial-and-error approaches.
A new study from Instituto Gulbenkian de Ciencia shows that leukemia can emerge as a consequence of prolonged precursor cells in the thymus. This blood cancer affects mostly children and is associated with a high risk of developing T-cell acute lymphoblastic leukemia.
Researchers discovered that STAT5B facilitates leukemogenesis in B-cell acute lymphocytic leukemia. They found that the absence of STAT5B increases interferon response and suppresses transformation. This understanding may enable precision medicine strategies to treat disease.
A new study led by St. Jude Children's Research Hospital found that high-risk leukemia patients did not experience improved long-term survival with bone marrow transplantation. Treatment guided by measuring minimal residual disease was associated with better outcomes, with 58% of patients becoming long-term survivors.
St. Jude Children's Research Hospital scientists identify 23 subtypes of B-cell acute lymphoblastic leukemia (B-ALL), including eight new subtypes, with distinct genomic and clinical features. The study's findings may lead to the development of precision medicines and customized treatments for high-risk patients.
Acute lymphoblastic leukemia (ALL) researchers find bone marrow stromal cells harbor leukemia cells, shielding them from chemotherapy. Yong-Mi Kim seeks integrin molecules to block treatment evasion.
Researchers at Nova Southeastern University have identified a genetic marker, NER gene expression levels, to predict early relapse in pediatric acute lymphoblastic leukemia (ALL) patients. This finding has the potential to guide targeted treatment and improve patient outcomes.
A Syracuse University physicist has developed tiny sensors that can detect and analyze protein-protein interactions in blood serum, which could lead to improved cancer detection. The technology, known as nanobiosensors, uses a nanopore to measure changes in electric current when proteins are present.
Scientists at Cold Spring Harbor Laboratory have identified ZFP64 as the single key to the cascade of events leading to mixed lineage leukemia (MLL), an aggressive blood cancer. Shutting down this protein may be a cure for MLL, which predominantly occurs in infants and is difficult to treat.
A study published in Cell Stem Cell found that the PPM1D gene confers a survival advantage to blood cells exposed to chemotherapy, potentially favoring the development of secondary leukemia. The research suggests that the presence of this gene and other mutations should be considered when choosing chemotherapies.
A low-fat diet has been shown to increase the survival rate of obese children with acute lymphoblastic leukemia by five times compared to a high-fat diet. This dietary intervention could potentially help kill cancer cells and improve treatment outcomes.
Researchers in Barcelona have received an ERC Synergy grant to study chronic lymphocytic leukemia at unprecedented resolution using single-cell analysis. The BCLL@las project aims to generate comprehensive information from thousands of individual cells, leading to novel insights into the origin and evolution of cancer.
Leukemia undercuts normal cells' ability to consume glucose, leading to a diabetic-like condition that favors cancer growth. Researchers have identified key strategies, including manipulating insulin production and gut bacteria, which can be targeted with low-tech therapies like serotonin supplementation.
Loyola will produce a more purified CAR-T cell product potentially reducing toxicities and costs. The Leukemia Research Foundation is supporting the research with a $250,000 grant.
A new study of 96 patients with chronic lymphocytic leukemia (CLL) found that those experiencing stress have higher levels of cancerous cells and cytokines in their blood. The researchers also discovered a link between stress and disease severity, even after controlling for other factors.
Scientists have introduced a microfluidic chip for manipulation and nucleic-acid analysis of individual cells. The technique uses dielectrophoresis to trap and analyze cells efficiently, overcoming conventional methods' limitations. This innovation paves the way for personalized medicine and improved diagnostics.
A team of researchers has discovered a protein called LEDGF/p75 that contributes to the regulation of gene expression in mixed lineage leukemia. The study found that this interaction is strongly modulated by phosphorylation from an enzyme called casein kinase 2, providing a new therapeutic route against the cancer.
A large cohort study found CLL patients have a 600% higher risk of melanoma compared to the general population. Close monitoring for early detection is crucial in managing this skin cancer with targeted therapies.
A study reveals that blocking heat shock transcription factor 1 (HSF1) signaling in T cell acute lymphoblastic leukemia (T-ALL) could represent a new approach in treating the aggressive disease. The discovery identifies a subset of T-ALL patients most likely to benefit from a new therapy.
Children with leukemia experience frequent vertebral fractures during chemotherapy, often persisting into adulthood. Vertebral deformities are more common in older children and those with severe collapse.
Researchers found that bacterial signals play a crucial role in developing pre-leukemic myeloproliferation, a precursor condition to leukemia, in mice with TET2 mutations. The study suggests that targeted treatments could reverse the disease by blocking aberrant IL-6 signals.
Researchers at Boston University School of Medicine identified ubiquitin-fusion degradation 1 (UFD1) as a key protein in aggressive T-cell leukemia. Reducing UFD1 levels by 50% inhibited leukemia development without impacting healthy tissues.
Researchers discovered genetic defects typical in ANKL, a shared genetic background with NK- and T-cell malignancies, and novel gene amplifications in the JAK-STAT signaling pathway. Potential drug candidates were found, including JAK inhibitors that could improve treatment for various NK-cell malignancies
Researchers identified a fourth gene, IKZF1, associated with childhood leukemia predisposition, expanding cancer screening options. Germline variants in IKZF1 increase the risk of developing B-cell acute lymphoblastic leukemia (ALL), a common pediatric cancer.
Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg have identified a new molecular cause of aggressive infant leukemia in children. The study found that changes in genes in white blood cells disrupt cell growth control, leading to the production of abnormal proteins that facilitate leukaemia.
Research from St. Jude Children's Research Hospital found that leukemia itself may increase the risk of long-term neurocognitive problems, even before treatment starts. Elevated biomarkers in cerebrospinal fluid indicate injury to brain cells, suggesting a complex interaction among genetics, treatment intensity, and other factors.
Two genes, JAK3/STAT5 and HOXA9, have been found to cooperate in triggering leukemia development. This cooperation leads to more rapid and aggressive disease progression. The discovery provides a basis for targeted therapies, not only for acute lymphoblastic leukemia but also for other leukemias.
A new technique using mass cytometry predicts relapse in acute lymphoblastic leukemia patients with 85% accuracy, identifying a subset of malignant cells that predispose to relapse. The method could lead to more precise treatment and targeted therapies for high-risk patients.
A global clinical trial of CAR T-cell therapy tisagenlecleucel found that 61% of children and young adults achieved complete remission after treatment, with durable responses lasting months or years. Most side effects were short-lived and reversible, with overall survival rates exceeding 90% at six months.
Researchers found that germline variations in the tumor suppressor gene TP53 predispose children to develop leukemia and increase their chances of developing a second cancer. The variants are associated with reduced gene activity and were five times more frequent in pediatric ALL patients than those without the disease.
Patients with advanced leukemia who rely on blood transfusions face barriers to quality end-of-life care, including limited hospice services and higher hospital deaths. Research suggests that improving access to blood transfusions could increase hospice care use among these patients.
Research found that leukemia patients who rely on blood transfusions face difficulties enrolling in hospice care, leading to shorter hospice stays and delayed access to palliative care. The study suggests that adding support for transfusions to the Medicare hospice benefit could maximize its benefits.
Research at Lund University found that HLF gene's failure to shut down leads to inadequate lymphocyte development, resulting in a single type of immune defense. The study aimed to identify mechanisms for breaking down leukemia, an aggressive blood cancer with poor prognosis.
Barbara Savoldo, MD, PhD, received a three-year grant to support research into an investigational CAR T-cell treatment for acute lymphoblastic leukemia with a built-in safety switch. The goal is to adapt an 'off switch' to reduce potentially lethal side effects of immunotherapy treatments.
A study by St. Jude Children's Research Hospital found that young leukemia patients who received the flu vaccine were still susceptible to flu infections, highlighting the need for additional measures to protect vulnerable individuals. Researchers emphasize the importance of hand washing and other precautions.
Hui Feng's research aims to understand why T-ALL is so aggressive and resistant to treatment. The grant will support further studies on the role of a novel protein contributor to leukemia's aggressiveness and its potential targeting through available drugs.
A team of scientists has identified a protein called TOX that drives the initiation and growth of an aggressive form of leukemia. TOX is expressed in 95 percent of human T-ALL cases and required for cancer's growth and persistence, offering new targeted treatment approaches.
Scientists at UC San Diego uncover a previously unknown link between non-coding DNA regions and the formation of immune cells. The discovery reveals a precise mechanism for the pairing of promoter and enhancer elements, which brings them into close proximity to initiate immune cell development.
Researchers at UT Southwestern Medical Center found that vitamin C regulates stem cell function and suppresses leukemia development. The study used mice with limited ascorbate production to mimic human levels and discovered a link between ascorbate, DNA modifications, and Tet2 enzyme activity.
Researchers have identified the KMT2A gene translocations as a common underlying cause of infant and treatment-related leukemias. The Penn/CHOP team has also found that topoisomerase II cleavage clusters in specific regions of the genome, which may play a role in DNA damage repair and cancer development.
A team of researchers has discovered that a DNA-cutting enzyme plays a broad role in driving abnormal genetic rearrangements, including translocations that cause cancer. The study identified specific sites of DNA damage along the entire genome of human leukemia cells.
Researchers developed an anti-PD-1 antibody that blocks PD-1/PD-L1 interaction, reinvigorating antivirus immune response and decreasing BLV counts. The new treatment could be effective against various intractable infectious diseases in cows.
Researchers discovered a protein signature that predicts leukemia, which could lead to novel treatments. The activation of STAT5 causes competition among proteins, leading to acute lymphoblastic leukemia.
A study published in Leukemia reveals an epigenetic lesion that correlates with the activation of a powerful oncogene capable of malignizing lymphocytes, leading to acute T-cell leukemia. The research suggests that targeting this gene may offer new treatment options for patients with this aggressive type of cancer.
A study using human stem cells found that deep space radiation may increase the risk of leukemia in humans. The research team identified a dietary supplement as a potential protector against these effects.
The OHSU Knight Cancer Institute research team discovered a previously unreported flaw in the standard leukemia assay, which can lead to non-functional mutations appearing functional. They recommend an additional sequencing step to improve the assay's accuracy and reproducibility.